Abstract

The rapid global spread of the coronavirus disease (COVID-19) has inflicted significant health and socioeconomic burden on affected countries. As positive cases continued to rise in Malaysia, public health laboratories experienced an overwhelming demand for COVID-19 screening. The confirmation of positive cases of COVID-19 has solely been based on the detection of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) using real-time reverse transcription polymerase chain reaction (qRT-PCR). In efforts to increase the cost-effectiveness and efficiency of COVID-19 screening, we evaluated the feasibility of pooling clinical Nasopharyngeal/Oropharyngeal (NP/OP) swab specimens during nucleic acid extraction without a reduction in sensitivity of qRT-PCR. Pools of 10 specimens were extracted and subsequently tested by qRT-PCR according to the WHO-Charité protocol. We demonstrated that the sample pooling method showed no loss of sensitivity. The effectiveness of the pooled testing strategy was evaluated on both retrospective and prospective samples, and the results showed a similar detection sensitivity compared to testing individual sample alone. This study demonstrates the feasibility of using a pooled testing strategy to increase testing capacity and conserve resources, especially when there is a high demand for disease testing.

Highlights

  • Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a newly discovered positive-sense single-stranded RNA coronavirus known as SARS-CoV-2

  • Extraction of nucleic acid from clinical NP/OP swab specimens in viral transport media (VTM) was performed using either DNeasy Blood and Tissue Kit (Qiagen, Germany) or Viral Nucleic Acid Extraction Kit II (Geneaid Biotech Ltd, Taiwan)

  • While maintaining the sensitivity of qRT-PCR detection of SARS-CoV-2, we investigated the minimal volume of specimen required for the assay

Read more

Summary

Introduction

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a newly discovered positive-sense single-stranded RNA coronavirus known as SARS-CoV-2. It was first recognized in Wuhan, Hubei province, China, in December 2019 [1, 2]. As of 11 August 2020, a total of 19,936,210 confirmed cases of SARS-CoV-2 infection and over 732,499deaths have. Sample pooling strategy for mass screening of COVID-19

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call